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Background: Venous thromboembolism (VTE) may complicate the course of Coronavirus Disease 2019 (COVID-
19).
Objectives: To evaluate the incidence of VTE in patients with COVID-19.
Methods: MEDLINE, EMBASE, and PubMed were searched up to 24th June 2020 for studies that evaluated the
incidence of VTE, including pulmonary embolism (PE) and/or deep vein thrombosis (DVT), in patients with
COVID-19. Pooled proportions with corresponding 95% confidence intervals (CI) and prediction intervals (PI)
were calculated by random-effect meta-analysis.
Results: 3487 patients from 30 studies were included. Based on very low-quality evidence due to heterogeneity
and risk of bias, the incidence of VTE was 26% (95% PI, 6%–66%). PE with or without DVT occurred in 12% of
patients (95% PI, 2%–46%) and DVT alone in 14% (95% PI, 1%–75%). Studies using standard algorithms for
clinically suspected VTE reported PE in 13% of patients (95% PI, 2%–57%) and DVT in 6% (95% PI, 0%–60%),
compared to 11% (95% PI, 2%–46%) and 24% (95% PI, 2%–85%) in studies using other diagnostic strategies or
patient sampling. In patients admitted to intensive care units, VTE occurred in 24% (95% PI, 5%–66%), PE in
19% (95% PI, 6%–47%), and DVT alone in 7% (95% PI, 0%–69%). Corresponding values in general wards were
respectively 9% (95% PI, 0%–94%), 4% (95% PI, 0%–100%), and 7% (95% CI, 1%–49%).
Conclusions: VTE represents a frequent complication in hospitalized COVID-19 patients and often occurs as PE.
The threshold for clinical suspicion should be low to trigger prompt diagnostic testing.
1. Introduction
Coronavirus disease 2019 (COVID-19) represents an unprecedented
threat to global health care systems with more than 4,900,000 cases
and over 300,000 deaths worldwide as of 22th May 2020 [1]. The se-
verity of COVID-19 varies between patients ranging from mild re-
spiratory disease to acute respiratory distress syndrome, shock, and
multi-organ failure associated with an increased risk of death [2]. The
clinical course of COVID-19 is often accompanied by a hyperin-
flammatory response and systemic coagulation derangement, which
may evolve into overt disseminated intravascular coagulopathy (DIC)
[3]. The systemic activation of blood coagulation and pulmonary
thrombo-inflammation with local vascular damage caused by COVID-
19 may increase the risk of venous thromboembolism (VTE) and pul-
monary artery thrombosis [4,5].
Since the start of the outbreak, several studies reported on the risk
of VTE in hospitalized patients with COVID-19. While initial observa-
tions showed a VTE incidence of 15–25%, more recent studies found
that VTE risk may be as high as 85% despite all patients receiving
pharmacological thromboprophylaxis [6–10]. The large variability may
be related to differences in patient sampling, hospital setting, and di-
agnostic protocols for VTE.
The objectives of this systematic review and meta-analysis were to
evaluate the incidence of VTE in patients admitted for COVID-19 and
identify subgroups at high risk.
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2. Materials and methods
This systematic review and meta-analysis was performed following
the Preferred Reporting Items for Systematic reviews and Meta-analysis
(PRISMA) guidelines [11].
2.1. Study search and selection
A systematic search of MEDLINE, EMBASE, and PubMed was per-
formed from 1st January 2020 up to 24th June 2020 for studies which
reported on VTE in hospitalized adult patients with COVID-19
(Supplementary Tables 1 to 3).
Two authors independently screened title, abstract, and full-text of
records identified from the search. The following inclusion criteria were
applied: (i) cohort study or RCT evaluating the incidence of VTE in
COVID-19; (ii) inclusion of ≥10 hospitalized patients with COVID-19.
Case reports and case series including less than 10 patients were ex-
cluded as they may report misleading results due to the small sample
size. Publications in languages other than English were not considered.
Any disagreement was resolved through discussion between the review
authors or involving a third review author.
2.2. Data extraction and risk of bias assessment
The following data were independently extracted by two review
authors: study characteristics (e.g. study design, country where study
was conducted, number of included patients, health-care setting), pa-
tients characteristics (e.g. age, sex, presence of comorbidities), antic-
oagulant treatment during hospitalization (e.g. type, dose, and duration
of anticoagulant therapy), number of patients who experienced VTE,
type and clinical presentation of VTE (symptomatic or incidentally
detected pulmonary embolism [PE] or deep vein thrombosis [DVT]).
Any disagreement was resolved by consensus between the two review
authors or by involving a third review author.
The primary outcome of interest was VTE which included objec-
tively diagnosed fatal or non-fatal PE and DVT of the upper or lower
limbs. Secondary outcomes were PE with or without DVT, and DVT
alone.
The risk of bias for observational studies was evaluated with the
methodological index for non-randomized studies (MINORS), while the
Cochrane tool was used to evaluate the quality of RCTs [12,13]. The
MINORS tool considers eight quality items which may be deemed as
adequate, inadequate, or unclear [12]. The item related to the endpoint
definition was considered appropriate if type of VTE and diagnostic
protocol used in the study were clearly specified. Follow-up duration
was considered adequate if the occurrence of VTE was assessed in all
patients included in the study until hospital discharge or death.
2.3. Statistical analysis
Categorical variables were described as counts and percentages and
continuous variables presented as median (interquartile range) or mean
(standard deviation), as appropriate. For meta-analytical purposes,
single proportions were logit transformed to maintain symmetry.
Summary estimates with the corresponding 95% prediction interval
(PI) and 95% confidence interval (CI) were calculated by random-effect
meta-analysis. The Wilson score was used to estimate CIs for the in-
dividual studies. As estimates of I-squared are uninformative in meta-
analyses of single proportions, the between-study heterogeneity was
evaluated by visual inspection of forest plots. The incidence of VTE was
evaluated according to hospital setting (i.e. intensive care unit [ICU]
versus general ward) and diagnostic protocol for VTE (standard diag-
nostic algorithm vs other) in random-effects subgroup meta-analyses.
Standard diagnostic algorithm was defined as the use of imaging tests in
Fig. 1. PRISMA flow diagram.
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Fig. 2. Summary risk of bias for included studies.
MINORS, methodological index for non-randomized studies.
Fig. 3. Incidence of venous thromboembolism in hospitalized patients with COVID-19.
Grey squares indicate individual study estimates of the proportion of the outcome, grey horizontal lines indicate 95% confidence intervals of the individual studies,
diamonds indicate summary estimates with 95% confidence intervals, and horizontal black lines represent 95% prediction intervals.
CI, confidence intervals; COVID-19, Coronavirus disease 2019; ES, estimates; ICU, intensive care unit; NR, not reported; PI, prediction intervals; VTE, venous
thromboembolism.
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case of clinical suspicion of VTE and/or sudden increase of D-dimer
levels [14,15]. In addition, we planned to analyse the incidence of VTE
according to dose of pharmacological prophylaxis, if data were avail-
able.
Statistical analyses were performed using R studio version 1.2.5001,
“meta” and “forest” packages [16].
3. Results
A total of 1381 records were identified from the database search
(Fig. 1). After removing 530 duplicates, 812 records were excluded by
title and abstract screening. Of the remaining 39 studies evaluated as
full-text, 30 were included with a total of 3487 patients. The inter-re-
viewer agreement was excellent with a kappa statistic of 0.90 [17].
The size of the included studies ranged from 12 to 400 patients
(Table 1). Four studies were prospective, 22 retrospective, and in 4 the
study design was unclear. Twenty-four studies were conducted in
Europe, three in China, and three in the United States. Fig. 2 shows the
summary risk of bias. Sixteen studies (70.0%) included patients con-
secutively and none had adequate follow-up duration with 33.7% of
patients (499/1480; 11 studies) still hospitalized at the end of the
study.
The mean age ranged between 57 and 70 years and 62.1% were
males (1951/3144; 25 studies). Seventy-two percent of patients (1008/
1395, 72.3%; 8 studies) were hospitalized in medical wards and 27.7%
were admitted to the ICU (387/1395; 8 studies). Eighteen studies
provided information on VTE risk factors: the presence of cancer was
reported in 8.7% of patients (178/2054; 16 studies) and previous VTE
in 4.0% (72/1785; 14 studies). Fifteen studies reported on antic-
oagulants for VTE prevention which were used at prophylactic doses in
73.2% of patients (2013/2751; 23 studies), intermediate doses in 8.0%
(67/837 patients; 7 study), and therapeutic doses in 16.8% (256/1526;
13 studies).
Data for both PE and DVT were available from 16 studies, whereas 6
reported only on PE and 7 only on DVT. Overall, the incidence of VTE
was 26% (95% PI, 6% to 66%; 752/3487 patients, Fig. 3), including PE
with or without DVT in 12% (95% PI, 2% to 46%; 386/2908 patients;
22 studies, Fig. 4) and DVT alone in 14% (95% PI, 1% to 75%; 347/
2672 patients; 23 studies, Fig. 5). Fourteen studies reported information
on the extension of PE which involved the main trunk or lobar pul-
monary arteries in 37.8% of cases (91/241; 12 studies), segmental ar-
teries in 37.9% (114/301; 12 studies), and subsegmental arteries in
19.0% (59/311; 13 studies). Thirteen studies reported on the extension
of DVT which involved the proximal veins in 32.2% of cases (88/273;
13 studies) and distal veins in 67.0% (136/203; 9 studies). Nine studies
failed to describe the diagnostic work-up for VTE, 9 studies used ima-
ging tests in case of clinically suspected VTE, and the remaining 12
studies used various approaches which included (serial) screening ul-
trasonography or patient sampling based on the availability of chest
computed tomography independently of VTE suspicion. In studies
which applied diagnostic tests only if thrombosis was clinically sus-
pected, VTE was diagnosed in 17% (95% PI, 2% to 71%), PE with or
without DVT in 13% (95% PI, 2% to 57%), and DVT alone in 6% (95%
PI, 0% to 60%). Higher estimates for VTE and DVT alone were reported
Fig. 4. Incidence of pulmonary embolism in hospitalized patients with COVID-19.
Grey squares indicate individual study estimates of the proportion of the outcome, grey horizontal lines indicate 95% confidence intervals of individual studies,
diamonds indicate summary estimates with 95% confidence intervals, and horizontal black lines represent 95% prediction intervals.
CI, confidence intervals; COVID-19, Coronavirus disease 2019; ES, estimates; ICU, intensive care unit; NR, not reported; PE, pulmonary embolism; PI, prediction
intervals.
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in studies using other diagnostic work-up or patient sampling (Figs. 3
and 5). Ten studies which performed screening ultrasonography for
DVT in all patients found a DVT incidence that varied widely between
0% and 85% and seemed to be largely accounted by asymptomatic
distal DVT [10,18].
In the analysis restricted to studies in ICU patients where referral to
imaging was based on clinical suspicion, VTE was diagnosed in 24%
(95% PI, 5% to 66%; 7 studies), PE with or without DVT in 19% (95%
PI, 6% to 47%; 10 studies), and DVT alone in 7% (95% PI, 0% to 69%; 6
studies, Supplementary Fig. 1). The corresponding values in patients
admitted to general wards were 9% (95% PI, 0% to 94%; 4 studies), 4%
(95% PI, 0% to 100%; 3 studies), and 7% (95% CI, 1% to 49%; 2 stu-
dies), respectively (Supplementary Fig. 2).
4. Discussion
This meta-analysis found that VTE occurs in a relevant proportion of
patients hospitalized for COVID-19. The incidence is higher in patients
admitted to ICU, but seems also substantial in patients of general wards
despite use of thromboprophylaxis. All prediction intervals were wide
indicating low confidence in the summary estimates.
The incidence of VTE in hospitalized COVID-19 patients appears to
be considerably higher compared to the incidence reported in previous
studies on acute medical patients and critically-ill patients with sepsis
or septic shock [19–21]. Most cases of VTE were represented by PE with
or without concomitant DVT. The combination of systemic activation of
coagulation, extensive pulmonary endotheliopathy and thrombo-in-
flammatory process caused by SARS-CoV2 may result in diffuse pul-
monary intravascular coagulopathy and pulmonary arterial thrombosis
[22–24]. The clinical presentation of PE may overlap with that of
COVID-19 pneumonia which may hindrance the recognition of PE
symptoms in patients who are already complaining of dyspnoea.
Therefore, current estimates may even represent an underestimation of
the actual PE incidence in COVID-19 as also suggested by autopsy
studies [25]. Nine studies followed standard diagnostic protocols for
suspected VTE, which included imaging tests performed only in cases of
clinical suspicion or sudden increase in D-dimer levels. Although the
incidence of VTE appeared to be lower compared to studies using other
diagnostic strategies or patient sampling, the risk of VTE remained
substantial with an average PE incidence that was as high as 19% in
patients admitted to ICU.
The risk of VTE seemed to remain considerable despite most pa-
tients received pharmacological thromboprophylaxis [7]. In all studies
the decision on the intensity and duration of anticoagulation for VTE
prevention was left to treating physicians limiting any conclusion about
optimal dosing in these patients. Whether higher doses of thrombo-
prophylaxis may reduce VTE without significantly increase the risk of
major bleeding is currently under evaluation in several RCTs
(NCT04345848, NCT04366960, NCT04416048, NCT04360824,
NCT04345848, NCT04445623, NCT04427098, NCT04373707). Anti-
inflammatory treatment may represent a potentially promising alter-
native to control inflammation-induced endotheliopathy and local
pulmonary thrombotic microangiopathy associated with COVID-19
[26,27].
The current meta-analysis has some limitations which warrant dis-
cussion. Most studies included a relatively small number of cases with
poor description of patient characteristics, which limited the possibility
to explore the effects of concomitant risk factors on the incidence of
VTE. The lack of randomization and the little data provided on the
incidence of VTE stratified by use, type, dose, and duration of
Fig. 5. Incidence of deep vein thrombosis in hospitalized patients with COVID-19.
Grey squares indicate individual study estimates of the proportion of the outcome, grey horizontal lines indicate 95% confidence intervals of the individual studies,
diamonds indicate summary estimates with 95% confidence intervals, and horizontal black lines represent 95% prediction intervals.
CI, confidence intervals; COVID-19, Coronavirus disease 2019; DVT, deep vein thrombosis; ES, estimates; ICU, intensive care unit; NR, not reported; PI, prediction
intervals.
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anticoagulation (i.e. prophylactic, intermediate, or therapeutic dose)
precluded subgroup analysis on the effects of pharmacological pro-
phylaxis. Based on scanty information available, we could only describe
the incidence of VTE according to the percentage of patients receiving
anticoagulation in each study (Figs. 3 to 5 and Supplementary Figures).
Five studies reported the incidence of bleeding complications which
ranged between 0% and 10.6% [28–32]. Two studies specified the
criteria used to define bleeding [28,29], and only two described whe-
ther bleeding events occurred on- or off-anticoagulation without pro-
viding information on the dose and type of pharmacological prophy-
laxis at the time of events [28,32]. One fifth of the studies provided no
information on the diagnostic work-up for VTE and about half failed to
report on both PE and DVT. The proportion of patients who were still in
hospital at the end of the study varied between 8% and 75.5%. As the
risk of VTE may persist beyond the first week of hospitalization, in-
adequate follow-up duration may have contributed to underestimating
VTE incidence.
5. Conclusion
VTE represents a frequent complication in patients admitted for
COVID-19 and often occurs as PE. Pooled incidences are based on very
low-quality evidence due to heterogeneity and risk of bias which re-
duces the confidence in the size of the estimates. Nevertheless, VTE
incidence appears to be high, and referral to imaging may be advisable
at a low threshold for VTE suspicion.
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